| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Relationship between the expression of secreted protein acidic and rich in cysteine (SPARC) and the efficacy of nab-paclitaxel in patients with gastric cancer was evaluated as a biomarker assessment. SPARC expression was observed in almost all localized in the stromal cells surrounding the cancer cells. In patients who were registered in phase II clinical trial, high SPARC expression was observed in effective cases, so it was suggested that SPARC expression could become a useful predicting biomarker of nab-paclitaxel efficacy.
In patients with gastric cancer who underwent curative resection, high stromal SPARC expression was found to be independent better prognostic factors. These relationships remained significant in patients with adjuvant chemotherapy, but not in patients without adjuvant chemotherapy. SPARC expression could predict the chemosensitivity in patients with gastric cancer who underwent curative resection.
|
